Media Pack
News

Current Edition

Volume 6 Issue 3

Upcoming Events

Advertisement

 
 
news

Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

Dive Brief: Taiho Pharmaceutical is buying back rights to an experimental cancer drug aimed at a genetic driver of lung tumors after licensing it to Cullinan Oncol...
13 May 2022 news cancer | Cullinan
Continue Reading →
news

Roche’s top immunotherapy prospect fails study in tough-to-treat lung cancer

Dive Brief: A drug combination including the Roche immunotherapy tiragolumab failed a Phase 3 trial in a tough-to-treat form of lung cancer, a setback for a closel...
1 April 2022 news cancer | Drug
Continue Reading →
news

How Merck’s ‘puzzling’ results could impact immunotherapy’s role in early lung cancer

An immunotherapy from Merck & Co. is the latest drug of its kind to slow the return of lung cancer in clinical testing, though mixed results in the large study su...
21 March 2022 news cancer | immunotherapy
Continue Reading →
news

EQRx builds case for cancer drug it hopes can disrupt market

Dive Brief: EQRx, which aims to bring new medicines to market at "radically lower" prices, said the experimental lung cancer drug it co-owns with Chinese biotech C...
20 January 2022 news cancer | Drug
Continue Reading →
news

Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

Novartis' testing of canakinumab, which works by curbing inflammatory signaling in cells, for the seemingly unrelated use in lung cancer stems from an intriguing 2011...
29 October 2021 news cancer | cells
Continue Reading →
 
 
 
 
 
IBI-white.png

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Facebook Linkedin
Bio Pharmaceutical Media © 2023, All Rights Reserved – Powered by Teksyte